IP Library Granted Patent US 10,378,002
Granted Patent B2
US 10,378,002 · App. 16/029,244 · Granted Aug 13, 2019

Replication conditional virus that specifically kills senescent cells

Inventors: Serge Lichtsteiner (Westlake, CA); Nathaniel David (Brisbane, CA)
Assignees: Unity Biotechnology, Inc.; Kythera Biopharmaceuticals, Inc.
C12N9/50A61K38/4873C12N15/85C12N2740/10043C12N2740/15043C12Y304/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,378,002
App. No.
16/029,244
Granted
Aug 13, 2019
Kind
B2
Abstract

Polypeptides, viruses, methods and compositions provided herein are useful for the selective elimination of senescent cells. Method aspects include methods for inducing apoptosis in a senescent cell comprising administering to the cell a polynucleotide, virus, host cell, or pharmaceutical composition described herein. Other methods include expressing a pro-apoptotic gene in a senescent cell comprising administering to the cell the polynucleotide, virus, or pharmaceutical composition as described herein.

Claims (10)

1. A senolytic virus, defined as a conditionally replicating virus having a recombinant genome construct in which a replication gene for the virus is placed under transcriptional control of one or more heterologous promoters,

wherein one of the heterologous promoters is the p16 promoter,

wherein when the senolytic virus is applied to a mixed cell population comprising senescent cells, the p16 promoter causes the virus to replicate preferentially in the senescent cells, thereby causing lysis of the senescent cells and selectively depleting them from the cell population.

2. The senolytic virus of claim 1 , wherein the genome construct comprises a replication gene for the virus placed under transcriptional control of a chemically inducible promoter.

3. The senolytic virus of claim 1 , which is an adenovirus.

4. The senolytic virus of claim 1 , which is a lentivirus, and the replication gene under transcriptional control of the p16 promoter is selected from gag, pol and env.

5. The senolytic virus of claim 1 , wherein the nucleotide sequence of the p16 promoter comprises SEQ. ID NO:1.

6. The senolytic virus of claim 1 , wherein the nucleotide sequence of the p16 promoter comprises SEQ. ID NO:2.

7. The senolytic virus of claim 1 , wherein the genome construct further comprises a caspase gene under transcriptional control of the p16 promoter.

8. A method of selectively depleting senescent cells from a mixed cell population or tissue, comprising combining the mixed population or tissue with a senolytic virus according to claim 1 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2019
From: LICHTSTEINER, SERGE PATRICK
To: KYTHERA BIOPHARMACEUTICALS, INC.
Reel/Frame 048740/0809 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2019
From: DAVID, NATHANIEL
To: CENEXYS, INC.
Reel/Frame 048740/0867 →
CHANGE OF NAME Recorded Mar 29, 2019
From: CENEXYS, INC.
To: UNITY BIOTECHNOLOGY, INC.
Reel/Frame 048749/0888 →
Continuity (3)
Division 14394854
Provisional Application 61625612 · Apr 17, 2012
Related Publication 20190136215A1 · May 9, 2019